Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Melphalan hydrochloride in relapsed or refractory multiple myeloma
NCT05438394Phase 1Unknown
- Sponsor
- Peking University People's Hospital
- Start
- Oct 2022
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of melphalan in multiple myeloma (MM), sponsored by Peking University People's Hospital. Primary endpoint: Dose limiting toxicity at 1 month. Status: unknown.
02
Drugs
melphalan
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT05438394.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05438394.